American Gene Technologies

AGT utilizes its own gene delivery platform to swiftly create patented gene and cell therapies that eradicate infectious disease, monogenic disorders, and cancers by addressing their genetic origins. AGT is in the process of developing and marketing genetic medicines that target significant diseases such as HIV/AIDS, Phenylketonuria (PKU), and Hepatocellular carcinoma (liver cancer, or HCC). Our therapeutic candidates have demonstrated initial proof of concept in early-stage studies and have the potential to provide cost-efficient treatments that are more precisely targeted and potent with reduced side effects. AGT's medications will address symptomatic disease.